文献速递眼底病与葡萄膜炎

6000次玻璃体内地塞米松植入剂注射的安全性

Safety of 6000 intravitreal dexamethasone implants.
PubMed 文献 · Br J Ophthalmol · 2019-04-30

这项回顾性多中心分析评估了6015次玻璃体内地塞米松植入剂(700 µg)注射在多种视网膜疾病中的真实安全性,共2736眼、1441例患者,平均随访18个月。结果显示白内障进展和眼压升高是最常见的不良事件,但多数可药物管理,眼内炎、视网膜脱离和玻璃体出血罕见,末次随访时视力与中心黄斑厚度无显著变化。

要点

  • 白内障需手术干预见于576眼(32.5%的有晶状体眼),另有259眼(14.6%)出现无需手术的视力不显著白内障进展。
  • 眼压>25 mm Hg见于727眼(26.5%),其中155眼(5.67%)有青光眼病史,572眼(20.9%)为新发眼压升高。
  • 眼压升高者中超过90%可药物管理,0.5%需滤过手术;眼内炎(0.07%)、视网膜脱离(0.03%)和玻璃体出血(0.03%)罕见。

核心结论

  • 本研究是评估玻璃体内地塞米松植入剂在多种视网膜疾病中安全性的最大规模真实世界研究,白内障进展和眼压升高是最常见副作用,但通常较易管理。

研究设计与样本

  • 回顾性多中心分析,纳入因多种视网膜疾病接受玻璃体内地塞米松植入剂(700 µg)注射的2736眼(1441例患者,平均年龄65.7±12.9岁),共6015次注射,平均随访18个月(范围6个月至102个月)。
  • 注射病因包括中央视网膜静脉阻塞(1861次注射)、糖尿病性黄斑水肿(3104次注射)、术后囊样黄斑水肿(305次注射)和葡萄膜炎(381次注射)。

主要发现

  • 576眼(32.5%的有晶状体眼)出现需手术干预的白内障,另有259眼(14.6%)出现视力不显著、无需手术的白内障进展。
  • 727眼(26.5%)出现眼压>25 mm Hg,其中155眼(5.67%)有青光眼病史,572眼(20.9%)为新发眼压升高。
  • 眼压升高者中超过90%经药物管理,0.5%需滤过手术;眼内炎发生率为0.07%,视网膜脱离为0.03%,玻璃体出血为0.03%。
  • 末次随访时视力(p=0.87)和中心黄斑厚度(p=0.12)无显著变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the real-life safety profile of intravitreal dexamethasone implant injection for various retinal conditions. METHODS: Retrospective multicenter analysis of intravitreal dexamethasone implant injections (700 µg) due to various retinal conditions including central retinal venous occlusion (1861 injections), diabetic macular oedema (3104 injections), post-surgical cystoid macular oedema (305 injections) and uveitis (381 injections). The eyes were evaluated mainly for the occurrence of adverse events such as glaucoma, cataract, retinal detachment and endophthalmitis along during the follow-up period. RESULTS: A total of 6015 injections in 2736 eyes of 1441 patients (mean age of 65.7±12.9 years) were in total analysed over an average period of 18 months (range 6 months to 102 months). A total of 576 eyes (32.5% of the phakic eyes) developed cataract requiring surgical intervention. However, visually insignificant cataract progression was observed in another 259 phakic eyes (14.6%) which did not require surgical removal. A total of 727 eyes (26.5%) experienced an intraocular pressure (IOP) rise of >25 mm Hg, with 155 eyes (5.67%) having a prior history of glaucoma and 572 eyes (20.9%) having new onset IOP rise. Overall, more than 90% of eyes with IOP rise were managed medically, and 0.5% eyes required filtering surgery. Endophthalmitis (0.07%), retinal detachment (0.03%) and vitreous haemorrhage (0.03%) were rare. There was no significant change in visual acuity (p=0.87) and central macular thickness (p=0.12) at the last follow-up. CONCLUSION: This is the largest real-life study assessing the safety of intravitreal dexamethasone implant injections in various retinal conditions. Cataract progression and intraocular pressure rise are the most common side effects, but are often rather easily manageable.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Rajesh B, Zarranz-Ventura J, Fung AT, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2019. PMID: 31040132. doi:10.1136/bjophthalmol-2019-313991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。